What are the potential adverse effects of maintaining a serum testosterone level of approximately 850 ng/dL in a 59‑year‑old man whose baseline testosterone was 450 ng/dL?

Adverse Effects of Maintaining Testosterone at 850 ng/dL in a 59-Year-Old Man

Maintaining a serum testosterone level of 850 ng/dL—which is above the recommended mid-normal target range of 450–600 ng/dL—significantly increases the risk of erythrocytosis and potentially cardiovascular complications, and the dose should be reduced by approximately 50% to achieve safer mid-normal levels.

Primary Safety Concern: Erythrocytosis

• Erythrocytosis is the most clinically significant adverse effect of testosterone therapy, occurring in 43.8% of men receiving injectable testosterone and 15.4% with transdermal preparations. 1
• Supraphysiologic testosterone levels (>600 ng/dL) markedly increase erythrocytosis risk because peak serum concentrations drive red blood cell production. 1, 2
• Elevated hematocrit increases blood viscosity, which can exacerbate coronary, cerebrovascular, and peripheral arterial disease—particularly hazardous in a 59-year-old man who may have subclinical cardiovascular risk factors. 1
• Hematocrit must be monitored at every visit; therapy should be withheld if hematocrit exceeds 54%, and therapeutic phlebotomy considered in high-risk cases. 1, 3

Cardiovascular Risk Considerations

• The 2023 TRAVERSE trial (5,246 men ages 45–80 with pre-existing cardiovascular risk) showed no significant increase in major adverse cardiac events with transdermal testosterone at therapeutic doses, but this study targeted mid-normal testosterone levels, not supraphysiologic concentrations. 1
• Injectable testosterone may carry greater cardiovascular risk than transdermal preparations due to time spent in supraphysiologic and subtherapeutic ranges, creating a "roller-coaster" pattern. 1, 2
• Peak testosterone levels occur 2–5 days after injection, and maintaining levels at 850 ng/dL suggests the patient is experiencing frequent supraphysiologic peaks that exceed 1,000 ng/dL. 1, 2

Lipid Profile Changes

• Testosterone therapy produces a modest increase in LDL cholesterol and a decrease in HDL cholesterol, with the magnitude of effect potentially greater at supraphysiologic levels. 1, 2
• A small decrease in HDL cholesterol (weighted mean difference -0.49 mg/dL) was observed in meta-analyses, though the clinical significance at therapeutic doses remains uncertain. 4
• Supraphysiologic testosterone concentrations are linked to adverse cardiovascular effects, notably significant HDL reduction, driven by systemic hormone levels rather than formulation. 2

Prostate-Related Effects

• Testosterone therapy can worsen benign prostatic hyperplasia (BPH) symptoms, though the risk is not dramatically elevated at physiologic replacement doses. 1, 5
• PSA monitoring is mandatory in men over 40 years; refer to urology if PSA rises >1.0 ng/mL within the first 6 months or >0.4 ng/mL per year thereafter. 1, 3
• Current evidence does not indicate that testosterone administration leads to progression of prostate cancer, but androgens play a permissive role in prostate disease development. 6

Other Potential Adverse Effects

• Fluid retention and edema can occur, particularly problematic in men with compromised cardiac reserve or heart failure. 5, 7
• Sleep apnea may worsen with testosterone therapy, especially at higher doses. 5, 7
• Gynecomastia can develop due to aromatization of excess testosterone to estradiol. 1, 5
• Testicular atrophy and suppression of spermatogenesis occur with exogenous testosterone through negative feedback on LH and FSH. 1, 6

Recommended Management Algorithm

Step 1: Immediate Dose Reduction

• Reduce the current testosterone dose by approximately 50% to bring levels into the target range of 450–600 ng/dL. 2
• For injectable testosterone, consider switching from bi-weekly to weekly dosing (e.g., 50–100 mg weekly instead of 100–200 mg every 2 weeks) to reduce peak-to-trough fluctuations. 1, 2
• Alternatively, switch from injectable to transdermal testosterone gel (1.62%, ~40 mg daily) to achieve more stable day-to-day levels and lower erythrocytosis risk. 1, 2

Step 2: Enhanced Monitoring

• Measure testosterone levels 2–3 months after dose adjustment, timing the draw midway between injections (days 5–7 for weekly dosing) and targeting 450–600 ng/dL. 1, 3, 2
• Check hematocrit at the same visit; if >52%, further dose reduction is required; if >54%, withhold therapy and consider phlebotomy. 1, 3
• Repeat PSA and perform digital rectal examination to ensure prostate safety. 1, 3
• Assess lipid profile to monitor HDL and LDL changes. 3, 2

Step 3: Ongoing Surveillance

• Continue monitoring every 3–6 months during the first year, then annually once stable levels are confirmed. 1, 3
• Evaluate clinical response, particularly sexual function and libido, which are the primary evidence-based indications for therapy. 8, 1
• If no improvement in sexual function is documented at 12 months, discontinue therapy to avoid unnecessary exposure to risks without benefit. 1

Critical Pitfalls to Avoid

• Do not continue the current dose even if the patient reports feeling well, as supraphysiologic levels increase adverse event risk without additional clinical benefit. 2
• Do not ignore mild erythrocytosis (hematocrit 50–52%) in a 59-year-old man, as even modest elevations increase blood viscosity and thrombotic risk in this age group. 1
• Do not rely on peak testosterone levels measured 2–5 days after injection, as supraphysiologic peaks do not reflect average exposure and may lead to inappropriate dose decisions. 1, 2
• Do not assume higher testosterone levels produce better outcomes; evidence shows only small improvements in sexual function (standardized mean difference 0.35) with little to no benefit for energy, physical function, mood, or cognition, even at therapeutic doses. 8, 1

Expected Outcomes After Dose Reduction

• Erythrocytosis risk will decrease substantially when testosterone levels are maintained in the mid-normal range (450–600 ng/dL). 1, 2
• Sexual function and libido benefits will be preserved, as these outcomes are achieved at mid-normal testosterone concentrations. 8, 1
• Cardiovascular and metabolic risks will be minimized by avoiding supraphysiologic exposure. 1, 2
• The patient's baseline testosterone of 450 ng/dL suggests he had borderline-low levels, meaning a target of 500–600 ng/dL represents appropriate physiologic replacement rather than supraphysiologic enhancement. 1, 3